NICE’s Rebranding of MTG19 to HTG344: A Missed Opportunity for Greater Impact in VTE Prophylaxis Marketing

NICE’s decision to reclassify MTG19 as HTG344 under its streamlined HealthTech programme is a classic example of bureaucratic reshuffling that offers minimal real-world benefit beyond administrative tidiness. While the consolidation of diagnostics, interventional procedures, and medical technologies under one umbrella might seem progressive on paper, it lacks the aggressive communication strategy necessary to truly elevate the geko® device within the competitive VTE prophylaxis landscape. Marketing professionals must recognize that a mere change in nomenclature without substantive updates or new endorsements does little to shift clinical adoption or payer enthusiasm.

The geko® device’s original guidance from 2014 remains relevant but underleveraged. The updated independent cost analysis revealing nearly double the initial estimated savings (£384 vs. £197 per patient) should be a clarion call for marketers to reposition the device as not only clinically effective but also a financially compelling alternative to standard VTE prophylaxis. This is especially critical given the increasing cost pressures on NHS trusts and hospitals globally. Yet, the lack of a proactive marketing narrative around these updated cost savings signals a disconnect between clinical value evidence and commercial exploitation.

Furthermore, the audit data from the Firstkind-NHS Trust partnership uncovers a glaring market opportunity that has been under-communicated: over a third of acute stroke patients cannot tolerate intermittent pneumatic compression (IPC), leaving a significant unmet clinical need. The geko device’s demonstrated equivalence in efficacy to IPC, coupled with a dramatic reduction in symptomatic VTE risk from 8.7% to 1.5%, should be front and center in any campaign aimed at stroke care units. Medical marketers must aggressively target stroke specialists and hospital procurement teams with these compelling clinical differentiators to accelerate adoption.

Critically, the geko device’s tolerability and role as a viable alternative for patients contraindicated for IPC is a narrative begging for amplification. In an era where patient-centric care and personalized medicine dominate healthcare conversations, marketers should leverage this unique positioning to break through the noise and secure formulary placements. The failure to do so risks ceding ground to competitors with more aggressive, data-driven marketing strategies.

In sum, the NICE update is a missed opportunity for stakeholders to reassert the geko device’s value proposition amidst evolving clinical guidelines and economic realities. Healthcare marketing professionals must move beyond passive reliance on NICE guidance and instead craft bold, evidence-backed campaigns that highlight cost savings, clinical efficacy, and patient tolerability to truly disrupt the VTE prophylaxis market.